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An unusual set of 3* coterminal, spliced mRNAs transcribed through the BamHI A fragment have been
previously identified in nasopharyngeal carcinoma (NPC) tissues. These RNAs have also been detected at low
levels in Burkitt’s lymphoma (BL) cell lines and Epstein-Barr virus (EBV)-transformed lymphocytes. Sequence
analyses of clones from a cDNA library derived from the C15 NPC tumor indicated that the primary transcripts
are differentially spliced, giving rise to a family of related transcripts, all of which encompass the BARF0 open
reading frame (ORF) at the 3* end of the transcripts. One cDNA was identified that extended the BARF0 ORF
at the 5* end, forming the RK-BARF0 ORF. In this study, a rabbit antiserum to a synthetic peptide repre-
senting an amino acid sequence encoded by the BARF0 ORF was prepared. This antiserum detected a
glutathione S-transferase–BARF0 fusion protein and both BARF0 and RK-BARF0 proteins expressed from
transfected constructs in H1299 cells. The serum also immunoprecipitated the 20-kDa BARF0 and 30-kDa
RK-BARF0 in vitro-translated proteins. Immunoblot analyses identified a protein doublet of 30 and 35 kDa in
all of the EBV-infected cell lines tested. Cellular fractionation studies revealed that the proteins were mem-
brane associated. The sizes of the proteins detected in cell lines and their association with membranes suggests
that they are likely encoded by the RK-BARF0 transcript, which is predicted to contain a membrane local-
ization signal. The proteins were also detected in protein extracts prepared from NPC biopsies and a BL biopsy
but not from hairy leukoplakia, a permissive EBV infection. These results reveal that the rightward RNA
transcripts from the BamHI A region of EBV encode one or more proteins that are expressed in latently
infected cells and in tumor tissue.
Epstein-Barr virus (EBV) is a herpesvirus that infects more
than 90% of the human population worldwide. EBV can infect
B lymphocytes and causes the B-cell lymphoproliferative dis-
eases, acute infectious mononucleosis, and posttransplant lym-
phoma (20, 23, 34). EBV is also linked to endemic Burkitt’s
lymphoma (BL) (13, 48). Infection of B lymphocytes with EBV
in vitro results in immortalized lymphoblastoid cell lines
(LCLs) (30, 31). These infections are usually nonpermissive,
with expression of only a limited number of viral genes. The
proteins expressed in this type of latent infection include a
family of EBV nuclear antigens, EBNA1, -2, -3A, -3B, -3C,
EBNA leader protein (EBNA-LP), and three membrane pro-
teins (LMP1, LMP 2A, and LMP2B). Three types of latency
have been described for lymphoid cell lines and infected tissues
(37). The pattern of expression detected in latently infected
lymphocytes is termed latency III. In some BL cell lines, viral
expression is tightly restricted and only the EBNA1 protein is
detected. This level of expression has been called latency I.
EBV also can infect epithelial cells and is detected in the
malignant epithelial cells in nasopharyngeal carcinoma (NPC),
a tumor that occurs with high incidence among southern Chi-
nese and Eskimos (9, 10, 33, 48). It has been shown that
EBV-associated NPC represents a clonal expansion of a single
EBV-infected progenitor cell, a finding that implies an etio-
logic role for the virus in these carcinomas (32). The EBV
genes encoding EBNA1, LMP1, and LMP2 are consistently
transcribed in NPC, a pattern of expression that is designated
latency II (6, 11, 45). In addition, a family of rightward tran-
scripts from the BamHI A region were originally identified in
NPC, where they are abundantly expressed (4, 7, 16, 17, 21).
Sequence analyses of clones obtained from a cDNA library of
tumor xenograft C15 revealed that the transcripts are differ-
entially spliced, giving rise to a family of related transcripts in
NPC tissues that are 39 coterminal (38, 40). All of the BamHI
A transcripts contain the open reading frame (ORF) BamHI A
rightward frame 0 (BARF0) at their 39 ends, which is predicted
to encode a 174-amino-acid (aa) protein. One cDNA that
extended this ORF at the 59 end, forming the RK-BARF0
ORF, which would encode a 279-aa protein, was obtained (38).
Previous studies using PCR analysis and Northern blot hy-
bridization detected BamHI A transcripts in EBV-positive BL
cell lines as well as in all EBV-transformed LCLs studied (7,
22, 38). Expression in established LCLs occurred irrespective
of their virus-producing status and was not a consequence of
continued in vitro passage, as spliced BamHI A transcripts
could be amplified from normal B cells within 1 day of exper-
imental infection (4). However, the steady-state level of tran-
scription in lymphoid cells was significantly lower than that in
NPC (7, 22, 38, 40). It has been postulated that the BamHI A
transcripts, to maintain the latent state of cells, may act as
antisense RNAs interfering with the expression of BamHI A
lytic cycle genes present on the complementary DNA strand
(22). The alternately spliced BamHI A RNAs contain several
potential ORFs that may encode one or more novel proteins,
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and in vitro-translated BARF0 protein was recognized by NPC
serum, suggesting that the BamHI A transcripts encode a pro-
tein that is expressed in vivo (17).
In this study a peptide corresponding to a region of the
putative BARF0 protein was synthesized and used to produce
a BARF0-specific antiserum. This anti-BARF0 antiserum re-
acted with 30- and 35-kDa proteins in EBV-positive cell lines
and in EBV-positive tumor biopsies. These data indicate that
one of the rightward RNA transcripts from the BamHI A
region of EBV encodes a protein that is expressed in latent
infection and in EBV-infected tumors in vivo.
MATERIALS AND METHODS
Cell lines. CB5 and SFC4 are human LCLs established by infection of cord
blood lymphocytes with either B95-8 virus or virus from throat washings from
human immunodeficiency virus (HIV)-positive patients, respectively. Mutu I and
Mutu III are two different clones of an EBV-positive BL cell line representing
type I latency and type III latency, respectively (19). Raji (25) and Akata (41, 42)
are EBV-positive BL cell lines exhibiting type III latency and type I latency,
respectively. Ramos is an EBV-negative BL cell line, BJAB is an EBV-negative
high-grade B-cell lymphoma, and Jurkat is an EBV-negative T-cell lymphoma
line. Lymphoid cell lines were maintained in RPMI 1640 medium containing
penicillin and streptomycin and supplemented with 10% fetal bovine serum. The
C33A cell line was derived from a human cervical carcinoma, and the H1299 cell
line was derived from a nonsmall cell lung carcinoma. Both cell lines were
maintained in Dulbecco’s modified Eagle’s medium containing penicillin and
streptomycin and supplemented with 10% fetal bovine serum.
Clinical samples. C15 is an NPC tumor xenograft that has been serially
passaged in athymic nude mice (5, 6). Four out of the five primary NPC biopsies
were obtained from Chinese patients living in Malaysia, and one biopsy was
obtained from an American Caucasian patient at University of North Carolina
Hospitals. All NPC tumors were identified clinically, were confirmed by histo-
pathology, and were classified as type I, II, or III according to the World Health
Organization (WHO) guidelines. Upon collection, the biopsy samples were im-
mediately placed in liquid nitrogen. The EBV-positive BL biopsy was clinically
diagnosed, and its EBV status was determined by Southern blot analysis. Both
squamous cell carcinomas (SCCs) were identified clinically, were confirmed by
histopathology, and were found to be EBV negative by Southern blot analysis.
Tongue biopsies were obtained from three HIV-positive patients with clinically
and pathologically identified oral hairy leukoplakia (OHL) as well as from three
clinically normal individuals. The presence of EBV in the OHL biopsies was
confirmed by Southern blot analyses.
Antibody production. A peptide (CTDSMAARVPIEELRELR) from the ami-
no-terminal portion of the putative BARF0 protein was synthesized and conju-
gated to keyhole limpet hemocyanin (KLH). Rabbits were immunized with this
peptide conjugate by Immuno-Dynamics Inc. (La Jolla, Calif.). Antisera were
screened for reactivity to a glutathione S-transferase (GST)-BARF0 fusion pro-
tein by immunoblotting.
Immunoblotting. Cells (2 3 107) were collected by centrifugation, resus-
pended in 400 ml of sodium dodecyl sulfate (SDS) sample buffer (5% [wt/vol]
sodium lauryl sulfate, 25 mM Tris hydroxymethyl aminomethane [pH 6.8], 5%
[vol/vol] 2-mercaptoethanol), and lysed by sonication. Cell samples were then
heated to 1008C for 5 min, followed by centrifugation at 15,000 3 g for 5 min.
Supernatants were collected, and 20-ml samples were subjected to SDS-poly-
acrylamide gel electrophoresis (SDS-PAGE). Tumor and OHL biopsies were
dispersed in 400 ml of sample buffer by sonication, and the mixtures were heated
to 1008C for 5 min and then were centrifuged at 15,000 3 g for 5 min. Super-
natants were collected, and 20-ml samples were subjected to SDS-PAGE. Equal
protein loading was confirmed by sample analysis SDS-PAGE and staining of the
gel with Coomassie brilliant blue (Sigma). Following SDS-PAGE, proteins were
electrophoretically transferred to nitrocellulose filters (Schleicher and Schuell)
with a semidry transfer apparatus (Hoefer). Filters were blocked by incubation in
Tris-buffered saline containing 0.1% Tween 20 and 5% nonfat dried milk
(BLOTTO). Antigens were detected with either anti-EBNA1 (1:1,000) (8), anti-
LMP1 S12 (1:10), or anti-FLAG M2 (1:350) monoclonal antibodies (Eastman
Kodak Co.) or anti-BARF0–anti-RK-BARF0 rabbit sera (1:2,000) followed by
incubation with horseradish peroxidase-conjugated antirabbit or antimouse an-
tibody (Amersham) and were visualized by enhanced chemiluminescence ac-
cording to the manufacturer’s specifications (Amersham).
Production of the GST-BARF0 fusion protein. The BARF0 gene was obtained
by PCR amplification of the BARF0 ORF from C15 DNA. Amplification was
performed using primers containing BamHI (59-ATCACGAGGGATCCATGG
CCGCCACCCTCCCCCTG-39) and BglII (59-ATCACGAGAGATCTTTAAT
GAAGAGAATCAATAGC-39) restriction enzyme sites to facilitate cloning.
PCR was performed for 35 cycles, with annealing at 558C for 30 s, extension at
728C for 30 s, and denaturation at 948C for 60 s. The amplified BARF0 was
ligated into the multiple cloning site of the pGEX-2TK vector (Pharmacia).
DNA sequencing confirmed the integrity of the BARF0 sequence. pGEX-2TK/
BARF0 and pGEX-2TK were used to transform Escherichia coli DH5a cells,
which were induced with isopropyl-b-D-thiogalactopyranoside (Sigma). The
GST-BARF0 fusion protein was purified by absorption to glutathione-Sepharose
agar (Pharmacia). The agarose beads were washed, resuspended in SDS sample
buffer, boiled, and centrifuged, and the supernatant was subjected to SDS-
PAGE.
Transient expression of BARF0-FLAG. The FLAG epitope was inserted into
the amino termini of both the BARF0 and RK-BARF0 ORF products by using
PCR primers to align the BARF0 and RK-BARF0 ATGs in frame with the
FLAG ATG. The entire RK-BARF0 ORF was constructed by PCR amplifica-
tion of two partially overlapping cDNAs, the 1.4-kb C25a cDNA (17) and the
RK1 cDNA (38), that were cut with AccI, ligated together, and used as a
template for additional PCR amplification with the 39 oligonucleotide primer
incorporating the BARF0 translation stop codon. The BARF0 and RK-BARF0
PCR products were cut with BamHI and BglII and were ligated into the pSG5-
FLAG expression vector. The pSG5-BARF0-FLAG and pSG5-RK-BARF0-
FLAG expression vectors, containing the FLAG-BARF0 or FLAG-RK-BARF0
sequence under control of the simian virus 40 early promoter, were transfected
into the H1299 cell line using lipofectin reagent (Gibco BRL). At 48 h after
transfection confluent cells were scraped from tissue culture dishes into SDS
sample buffer. Cell extracts were subjected to SDS-PAGE and were immunob-
lotted with either anti-BARF0 or anti-FLAG antisera.
In vitro translation of BARF0 and RK-BARF0 proteins. The BARF0 and
RK-BARF0 cDNAs were cloned into the pSG5 vector which contains a T7
promoter. [14C]leucine-radiolabelled BARF0 and RK-BARF0 proteins were
synthesized in vitro with the TNT T7 reticulocyte lysate system (Promega, Mad-
ison, Wis.). The radiolabelled in vitro-translated proteins were immunoprecipi-
tated with the anti-BARF0 rabbit serum or control rabbit serum for 2 h at 48C.
The immune complex was collected by incubation with pansorbin for 16 h at 48C
followed by centrifugation at 15,000 3 g for 5 min. The immunoprecipitate was
then washed three times with Tris-buffered saline containing 0.1% Tween 20
(TBST) buffer, followed by two washes in 23 TBST and finally one wash in TBST
containing 0.1% SDS. The precipitates were solubilized in SDS buffer, heated to
1008C for 5 min, and subjected to SDS-PAGE, and radiolabelled protein was
visualized by fluorography.
Cell fractionation. CB5 cells were pelleted, washed with phosphate-buffered
saline, and resuspended in HEM buffer (20 mM HEPES, 1 mM EDTA, 1 mM
b-mercaptoethanol, and the protease inhibitors aprotinin, leupeptin, and phe-
nylmethylsulfonyl fluoride). The cells were lysed by Dounce homogenization,
and nuclei were collected by centrifugation at 750 3 g for 5 min. Cell extracts
were kept at 48C for 5 min, and any remaining intact nuclei were again collected
by centrifugation at 750 3 g for 5 min. The supernatant was collected, and a
crude membrane fraction was obtained by centrifugation at 43,000 3 g for 20
min. The remaining supernatant represented the cytoplasmic fraction. The nu-
clear and membrane fractions were dispersed directly into SDS sample buffer,
whereas protein in the soluble fraction was first precipitated by the addition of six
volumes of acetone before being solubilized in SDS sample buffer. Equal protein
loading on SDS-PAGE gels was determined by staining gels with Coomassie
brilliant blue.
RESULTS
Generation of BARF0-specific antisera. On the basis of the
predicted amino acid sequence encoded by the BARF0 ORF,
an 18-mer peptide was synthesized. To allow convenient cou-
pling of the peptide to KLH, the peptide was produced begin-
ning with an N-terminal cysteine. The peptide-KLH conjugate
was used to raise antisera in rabbits, and serum samples were
assayed for reactivity to a GST-BARF0 fusion protein by im-
munoblotting. Serum from one rabbit (2161) reacted with the
GST-BARF0 fusion protein but not with GST alone (Fig. 1A).
A FLAG epitope was added to the amino termini of both the
BARF0 and RK-BARF0 ORF products by PCR. These con-
structs were used to confirm the specificities of the antisera by
transient expression of the FLAG epitope-tagged constructs in
H1299 cells. The BARF0-FLAG fusion protein was detected
as a 22-kDa protein by immunoblotting with both the anti-
FLAG antiserum and rabbit 2161 serum (Fig. 1B). Immuno-
blotting with both the anti-FLAG antiserum and rabbit 2161
serum also detected the RK-BARF0-FLAG fusion protein
(Fig. 1C). These data indicate that rabbit 2161 serum reacts
with the BARF0 and RK-BARF0 proteins expressed in vivo
and reveal an absence of reactivity in cells transfected with the
control vector.
The BARF0 and RK-BARF0 ORFs were translated in vitro
in the presence of [14C]leucine, and the products were immu-
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noprecipitated with either serum from rabbit 2161 or serum
from a rabbit immunized with an unrelated peptide (Fig. 1D).
As expected from the predicted amino acid sequences of the
BARF0 and RK-BARF0 proteins, the in vitro-synthesized pro-
teins migrated on SDS-PAGE gel with estimated molecular
masses of approximately 20 (BARF0) and 30 kDa (RK-
BARF0). The considerable amount of hemoglobin in the di-
rect load affects the migration of the BARF0 and RK-BARF0
in vitro-translated proteins, which are detected as diffuse
bands. However, additional experiments with less protein re-
vealed that only one protein of either 20 or 30 kDa was de-
tected in the direct load. Both BARF0 and RK-BARF0 pro-
teins were immunoprecipitated by serum from rabbit 2161 but
not by the unrelated serum, indicating that rabbit 2161 serum
contained antibodies specific for the BARF0 ORF product.
This serum did not immunoprecipitate other in vitro-translated
products, including a 126-aa-encoding ORF present in the
previously identified RB2 cDNA and a 103-aa-encoding ORF
in the RK1 cDNA, both of which are transcribed in NPC (data
not shown) (38).
Identification of RK-BARF0 in EBV-infected cell lines. To
determine whether the BARF0 protein was expressed in EBV-
transformed cell lines, cell extracts were prepared and ana-
lyzed by immunoblotting. SDS extracts were prepared from
two EBV-transformed B-cell lines (CB5 and SFC4), three BL
cell lines (Raji, Mutu I, and Mutu III), and three EBV-nega-
tive epithelial and lymphoid cell lines (C33A, Jurkat, and
Ramos). These samples were subjected to electrophoresis on
SDS–12% PAGE gel, transferred to nitrocellulose, and immu-
noblotted with anti-BARF0 serum (Fig. 2). Two proteins with
approximate molecular masses of 30 and 35 kDa were detected
in the EBV-positive cell lines but not in the EBV-negative
lines. Two proteins of the same size were also detected in
neonatal lymphocytes 14 days postinfection with B95-8 virus,
but they were not detected in the neonatal lymphocytes prior
to infection (data not shown). The serum also reacted with
proteins at 20 and 69 kDa in some of the cell lines, including
the EBV-negative Jurkat cell line. Rabbit antiserum that was
affinity purified with Sepharose conjugated with synthetic pep-
tide also reacted specifically with the 30- to 35-kDa proteins,
demonstrating that this reaction was not due to nonspecific
antibodies in the rabbit serum (data not shown).
These results indicated that two proteins with molecular
masses of 30 and 35 kDa are expressed in vivo and were
identified with the BARF0-specific antiserum. The molecular
masses of the proteins identified in vivo suggest that they
represent the 30-kDa RK-BARF0 gene product rather than
the 20-kDa BARF0 gene product. The in vitro-translated RK-
BARF0 migrates at the same position as the lower 30-kDa
band, while the transfected RK-BARF0-FLAG migrates at 35
kDa, the same size as that of the upper band. This suggests that
the 35-kDa protein represents a posttranscriptional modifica-
tion of the 30-kDa RK-BARF0 protein that occurs in vivo in
transfected cells but not in the in vitro translations.
Cellular localization of RK-BARF0. To investigate the cel-
lular localization of RK-BARF0, cells were separated into nu-
FIG. 1. Reactivity of rabbit serum to BARF0 and RK-BARF0 proteins. Se-
rum from rabbit 2161 was used to detect a GST-BARF0 fusion protein (A) and
transiently transfected BARF0 (B), transiently transfected RK-BARF0 (C), and
in vitro-translated BARF0 and RK-BARF0 proteins (D). In panel A GST (lane
1) and GST-BARF0 (lane 2) were subjected to SDS–10% PAGE, immunoblot-
ted, and reacted with rabbit 2161 serum. In panel B the BARF0 gene, which
contains additional nucleotides encoding the FLAG sequence, was transiently
transfected into H1299 cells (lane 1) as well as the vector control (lane 2). The
expressed BARF0-FLAG protein was detected by immunoblotting with either
rabbit 2161 serum or anti-FLAGmonoclonal serum. In panel C H1299 cells were
transfected with the vector control (lane 1) or the RK-BARF0-FLAG expression
vector (lane 2). Rabbit 2161 serum and anti-FLAG monoclonal serum were also
used to detect the RK-BARF0-FLAG fusion protein. In panel D radiolabelled
BARF0 and RK-BARF0 proteins were in vitro translated, immunoprecipitated
with either rabbit 2161 serum or control rabbit serum, and subjected to SDS–
12% PAGE. Samples of the direct loads (lane 1) as well as the immunoprecipi-
tates with the rabbit 2161 serum (lane 2) and control serum (lane 3) are shown.
kd, kilodaltons.
FIG. 2. Detection of RK-BARF0 in cell lines. Samples of five EBV-positive
cell lines (SFC4, Raji, Mutu I, Mutu III, and CB5) and three EBV-negative cell
lines (C33A, Jurkat and Ramos) were subjected to SDS-PAGE and immuno-
blotting. RK-BARF0 was detected with anti-BARF0 antiserum. The position of
RK-BARF0 is shown as well as the positions of the molecular mass standards.
kd, kilodaltons.
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clear, cytoplasmic, and membrane fractions prior to immuno-
blotting. The EBV-transformed CB5 cell line was used because
of the high level of RK-BARF0 protein expressed in these cells
(Fig. 2). Samples of the nuclear, cytoplasmic, and membrane
fractions were subjected to electrophoresis through SDS–12%
PAGE gel, transferred to nitrocellulose, and immunoblotted
with either anti-BARF0 serum, anti-EBNA1 monoclonal anti-
body, or anti-LMP1 monoclonal antibody (Fig. 3). The 73-kDa
EBNA1 protein was detected in both the nuclear and cytoplas-
mic extracts as expected (39), whereas the 63-kDa LMP1 pro-
tein was predominantly detected in the membrane fraction.
The RK-BARF0 protein was detected only in the membrane
preparation, suggesting that the protein is membrane associ-
ated. The amino terminus of RK-BARF0 contains a strongly
hydrophobic region that may function as an endoplasmic re-
ticulum-targeting signal peptide (38).
Expression of RK-BARF0 after induction of EBV viral rep-
lication. To determine if BARF0-related proteins function
during replication and to explore the possibility that RK-
BARF0 functions in restricting EBV viral replication, as has
been suggested for the BamHI A RNA transcripts (22), the
expression of RK-BARF0 was analyzed after induction of
Akata cells. EBV replication was induced in Akata cells by the
addition of anti-immunoglobulin G, and samples were taken at
different time intervals up to 96 h postinduction. These cell
samples were then subjected to SDS-PAGE and immunoblot-
ting. The degree of induction of EBV was determined with a
monoclonal antibody to the EBV replication activator, BZLF1,
while the expression of RK-BARF0 was measured with anti-
BARF0 serum (Fig. 4). The level of expression of the BZLF1
gene product increased significantly up to 10 h postinduction,
after which time its level of expression remained constant,
indicating successful induction of EBV replication. RK-
BARF0 also increased by 10 h postinduction. The increase in
RK-BARF0 indicates that the protein is not involved in re-
stricting replication of EBV. The presence of RK-BARF0 in
the CB5 cell line, which is tightly latent as indicated by the lack
of BZLF1 expression, implies that RK-BARF0 is a latent pro-
tein. However the increase in expression of RK-BARF0 fol-
lowing induction may indicate that the protein functions during
both latency and replication. In addition, a 20-kDa protein was
detected at low levels approximately 24 h postinduction. This
protein may represent the BARF0 protein, suggesting that
BARF0 may be expressed during EBV replication.
Expression of RK-BARF0 in EBV-infected tissues. Since the
BamHI A transcripts were originally identified in NPC tumor
samples where the transcripts are considerably more abundant
than in lymphoid cell lines, RK-BARF0 protein expression was
analyzed in a number of different tumor biopsies. SDS cell
extracts were prepared from six NPC biopsies, including one
NPC metastasis, one BL biopsy, and two EBV-negative SCC
biopsies. These extracts were then subjected to immunoblot-
FIG. 3. Cellular localization of RK-BARF0. CB5 cells were separated into
nuclear, cytoplasmic, and membrane fractions. Equal protein samples of each
fraction were subjected to SDS-PAGE and immunoblotting. Proteins were de-
tected with either the anti-BARF0 antiserum, the anti-LMP1 monoclonal anti-
serum, or the anti-EBNA1 monoclonal antiserum. The positions of RK-BARF0,
LMP1, and EBNA1 are shown. kd, kilodaltons.
FIG. 4. Detection of RK-BARF0 in Akata cells following induction of EBV
replication. Akata cells were induced for EBV virus production with anti-immu-
noglobulin G. Samples were taken following induction and were subjected to
SDS-PAGE and immunoblotting. Evidence of successful induction was deter-
mined by detection of BZLF1 expression with anti-BZLF1 antiserum. RK-
BARF0 was detected with anti-BARF0 antiserum. The EBV-positive CB5 cell
line and the EBV-negative BJAB cell line are included as controls. The positions
of BZLF1 and RK-BARF0 are indicated, as are the positions of the molecular
mass standards. kd, kilodaltons.
FIG. 5. Immunoblot of tumor biopsies. SDS extracts were prepared from six
NPC biopsies (including one metastasis), two SCC biopsies, one BL biopsy, one
nude mouse-passaged NPC (C15), two EBV-negative cell lines (Ramos and
BJAB), and one EBV-positive cell line (CB5). These extracts were subjected to
SDS-PAGE and immunoblotting with anti-BARF0 antiserum. The position of
RK-BARF0 as well as those of the molecular mass standards are indicated. The
numbers next to the primary NPC biopsies are the WHO classifications.
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ting with the BARF0 antiserum (Fig. 5). The 30- to 35-kDa
RK-BARF0 protein was not detected in the EBV-negative
B-cell lines Ramos and BJAB or the two EBV-negative SCC
samples. RK-BARF0 was detected in the EBV-positive CB5
cell line and in the C15 tumor xenograft as well as in five of the
six NPC tumor biopsies. The NPC biopsy in which RK-BARF0
was not detected was a small sample of a WHO 1 NPC sample;
it is possible that the sample processed for biochemical analysis
lacked sufficient tumor material. In the EBV-positive BL bi-
opsy and two of the NPC samples, only the 30-kDa protein was
detected. The apparent absence of the 35-kDa component in
these samples could reflect differences in abundance of the
proteins or differences in posttranslational processing in some
tumor samples.
The AIDS-associated lesion OHL represents a permissive
EBV infection characterized by abundant linear EBV DNA,
expression of replicative gene products, and lack of expression
of the small nuclear EBV-encoded RNAs (EBERs) (15, 18).
Oral biopsies were obtained from three HIV-positive individ-
uals with clinically apparent OHL as well as samples of the
lateral border of the tongue from three healthy individuals.
Immunoblots prepared with extracts from these samples were
reacted with anti-BARF0 and anti-BZLF1 antisera (Fig. 6).
BZLF1 protein was detected in each of the OHL lesions as
well as in Akata cells 48 h after induction of virus production.
BZLF1 was not detected in any of the tissue samples from
healthy individuals, in uninduced Akata cells, or the two EBV-
negative cell lines, BJAB and C33A. RK-BARF0 was not de-
tected in any of the OHL samples or in the biopsies of normal
tissue but was detected in both the uninduced and induced
Akata cell lines.
Besides detecting RK-BARF0, the rabbit serum also reacted
with proteins in the molecular mass range of 46 to 69 kDa.
These proteins were present in both NPC biopsy samples and
in EBV-negative SCC biopsies, as well as in the biopsies of
OHL and normal tissue, and most likely reflect nonspecific
reactivity of the antiserum with cellular proteins. These pro-
teins were also detected with the preimmune serum from rab-
bit 2161, providing additional evidence that these bands are
nonspecific (data not shown).
DISCUSSION
The data presented in this study indicate that an RNA tran-
script from the BamHI A region of EBV encodes a protein that
is expressed in vivo. The rabbit serum produced by immuniza-
tion with an N-terminal BARF0 peptide contains antibodies
that are specific for the protein encoded by the BARF0 ORF,
as demonstrated by its reactivity on immunoblots to a GST-
BARF0 fusion protein, but not to GST alone, and to both the
BARF0-FLAG and RK-BARF0-FLAG fusion proteins trans-
fected into H1299 cells. The serum also immunoprecipitates
radiolabelled, in vitro-translated BARF0 and RK-BARF0.
The molecular masses of the proteins detected on immuno-
blots, 30 and 35 kDa, suggest that they most likely represent
the RK-BARF0 ORF, which encodes a 30-kDa protein when
translated in vitro and whose product is detected as a 35-kDa
protein when H1299 cells are transfected with a RK-BARF0-
FLAG expression construct. This suggests that the 35-kDa
protein detected in transfected cells and tumor lysates likely
represents a posttranslational modification of RK-BARF0 that
occurs in vivo but not in reticulocyte lysates. The detection of
the 30- and 35-kDa proteins in the membrane fraction also
suggests that they represent the RK-BARF0 ORF. The RK-
BARF0 ORF contains a strongly hydrophobic region that cor-
responds to an endoplasmic reticulum-targeting signal peptide
sequence that is absent from the BARF0 ORF (38), suggesting
that RK-BARF0 is a membrane protein.
It has been previously demonstrated that the BamHI A
region of EBV is not necessary for transformation of lympho-
cytes by the virus (35). However, the RK-BARF0 protein was
detected in two tightly latent LCLs, CB5 and SFC4, and in
neonatal lymphocytes early after infection, suggesting that it
functions during latency. At least two other genes, EBNA3B
and LMP2, that are consistently expressed in latently infected
lymphocytes are also not essential for B-lymphocyte transfor-
mation (24, 27–29, 43). That these genes are retained by the
virus and consistently expressed in transformed cells suggests
that they probably contribute in some way to infection in vivo.
RK-BARF0 may also be an important component of infection
in vivo.
It is also possible that RK-BARF0 may be essential for
latent infection of epithelial cells, which at present cannot be
assessed in vitro. BamHI A transcription is significantly higher
in NPC than in BL or LCLs, and the relative level of RK-
BARF0, as judged by immunoblotting, was higher in the C15
tumor line than in any of the BL or LCLs examined (4, 22). It
is of particular interest that RK-BARF0 was consistently de-
tected in NPC, which represents latently infected epithelial
cells, but was not found in OHL, a permissively infected epi-
thelial cell lesion. These findings suggest that RK-BARF0 is
important in latent epithelial infection but is not essential for
viral replication. However, the RK-BARF0 protein was also
detected in Akata cells and increased after induction of viral
replication, suggesting that it may also function during repli-
cation. EBV LMP1, an essential latent protein, also increases
during replication, although it is unknown how it contributes to
replication (36). The increase in RK-BARF0 protein after
induction of replication suggests that it does not restrict viral
replication, while the absence of detectable RK-BARF0 in the
permissively infected OHL lesions suggests that any replicative
function of the protein may be restricted to viral reactivation
and replication in B cells.
The 20-kDa protein expressed in Akata cells at low levels
FIG. 6. Immunoblot of OHL lesions. Biopsies of OHL lesions from three
HIV-positive patients (OHL1 to OHL3) and lateral tongue border biopsies from
three healthy individuals (N1 to N3) were sonicated in SDS buffer. SDS extracts
were also prepared from Akata cells (uninduced and induced for 48 h) and from
C33A and BJAB, two EBV-negative cell lines. The extracts were subjected to
SDS-PAGE and were immunoblotted with either anti-BARF0 or anti-BZLF1
monoclonal antiserum. The positions of RK-BARF0, BZLF1, and the molecular
mass standards are indicated. kd, kilodaltons.
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24 h postinduction and in the EBV-positive SFC4 cell line may
represent the protein encoded by the BARF0 ORF. This may
indicate that the 20-kDa BARF0 protein functions during viral
replication. This protein has the same molecular weight as the
product of the BARF0 ORF translated in vitro; however, a
protein with a similar molecular weight was also detected in
the EBV-negative BL cell line, Ramos. Therefore, this protein
could represent a cellular protein that is detected because of
nonspecific cross-reactivity of the antiserum.
There are several striking differences in EBV expression
between latently infected NPC tissues and latently infected,
transformed lymphocytes. The EBNA2, -3A, -3B, -3C, and -LP
proteins are not detected in NPC but are consistently ex-
pressed in B lymphocytes. The functions of all of these proteins
are not known; however, EBNA2 and -3C regulate expression
of LMP1 and LMP2A and LMP2B (1, 2, 3, 12, 14, 44, 46, 47).
It is possible that the BamHI A proteins contribute to viral
regulation of gene expression in the absence of the EBNA
proteins. The BARF0 ORF encodes three arginine-rich motifs
that mark proteins with RNA binding properties (38). This
suggests that the BARF0 protein could bind RNA and affect
transport and/or processing of viral mRNAs.
The RK-BARF0 protein was also detected in a group I BL
cell line (Mutu I) and in a BL biopsy. EBNA1 has been the
only viral protein thought to be expressed in BL cells. As yet,
cytotoxic T cells specific for EBNA1 have not been identified.
EBNA1 is apparently specifically excluded from proteolytic
processing and presentation by class I molecules; this property
is conferred by a glycine/alanine repeat sequence present in the
EBNA1 protein (26). In other viral infections, viral proteins
that impair presentation of viral proteins within class I mole-
cules have been identified. It is possible that RK-BARF0 also
interferes with this process and enables expression of immu-
nogenic proteins without immune recognition. It will be im-
portant to identify more precisely the intracellular locations of
the RK-BARF0 protein and interacting cellular proteins to
determine the RK-BARF0 protein’s molecular properties.
However, the detection of RK-BARF0 proteins in both epi-
thelial tumors and B-cell tumors suggests that their expression
is an important component of EBV-induced neoplasia.
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